Dr. Reddy's Laboratories Limited (DRREDDY) secures marketing authorization for generic semaglutide injection in Brazil, expanding its diabetes treatment opti.
Dr. Reddy's Laboratories Limited DRREDDY reports double-digit Q2FY27 growth, with ₹8,671 Cr revenue and 20.6% EBITDA margin.
Dr. Reddy's Laboratories Ltd. (NSE: DRREDDY) announced DCGI approval for Zytorvi® in advanced esophageal squamous cell carcinoma.
Dr. Reddy's Laboratories Limited (DRREDDY) to announce Q2FY27 results on October 23rd, focusing on earnings and revenue insights.
Dr. Reddy's Laboratories Ltd. (NSE: DRREDDY) receives FDA approval for its rituximab biosimilar, expanding its global biosimilars portfolio.
Dr. Reddy's Laboratories Limited (NSE: DRREDDY) stock price falls 6% intraday to ₹1266.7, bouncing from support in the Healthcare sector.
Dr. Reddy's Laboratories Limited (DRREDDY) announces the first-to-market launch of Bosutinib Tablets 400mg in the U.S., expanding its oncology portfolio.
Dr. Reddy's Laboratories Ltd. (NSE: DRREDDY) to celebrate 25 years on NYSE with Closing Bell ceremony.
Dr. Reddy's Laboratories Limited DRREDDY reports strong Q4 & FY26 results with double-digit growth and strategic milestones.